EUVIMEDEUVIMED entdecken
Open Access

Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells

Lipeng Xu, Ling Qin, Wenying Zhao

In Vivo · 2026-11 · 40 (6) · 3504-3518

DOI: 10.21873/invivo.14493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Lipeng Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China; xlp1393@163.com. Hauptthemen laut MEDLINE: Sorafenib, MicroRNAs, Hyaluronan Receptors, Carcinoma, Hepatocellular. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibMicroRNAsHyaluronan ReceptorsCarcinoma, HepatocellularLiver NeoplasmsNanoparticlesAntineoplastic AgentsNiacinamideAntagomirsPhenylurea CompoundsHumansSignal TransductionApoptosisCell ProliferationHep G2 CellsDrug CarriersSTAT3 Transcription FactorCell MovementDendrimersPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktGene Expression Regulation, NeoplasticPTEN PhosphohydrolaseCell Line, TumorRNA-Binding ProteinsApoptosis Regulatory Proteins

Stichwörter der Autor:innen

Hepatocellular carcinomacombination therapymicroRNA-21sorafenibtargeted nanotherapy

Substanzen

SorafenibMicroRNAsHyaluronan ReceptorsMIRN21 microRNA, humanDrug CarriersCD44 protein, humanSTAT3 Transcription FactorAntineoplastic AgentsDendrimersPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China; xlp1393@163.com.
  • Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China.
  • Department of Medical Oncology, the First Affiliated Hospital of Wannan Medical College, Wuhu, P.R. China zwy815@126.com.

Zitieren

APA

Xu, L., Qin, L., & Zhao, W. (2026). Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells. In Vivo, 40(6), 3504-3518. https://doi.org/10.21873/invivo.14493

Vancouver

Xu L, Qin L, Zhao W. Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells. In Vivo. 2026;40(6):3504-3518. doi:10.21873/invivo.14493

BibTeX
@article{Xu2026,
  author = {Xu, Lipeng and Qin, Ling and Zhao, Wenying},
  title = {Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3504--3518},
  doi = {10.21873/invivo.14493}
}
Kostenlos starten →